Department of Cardiology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark.
Department of Cardiology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark.
Am Heart J. 2023 Oct;264:183-189. doi: 10.1016/j.ahj.2023.05.007. Epub 2023 May 11.
Valve-in-valve-transcatheter aortic valve implantation (TAVI) is a feasible and increasingly used treatment option for failed surgical aortic prosthesis, but data from clinical practice are limited. We aimed to examine patient characteristics and outcomes of patients undergoing TAVI in a surgival valve (valve-in-valve TAVI) compared with patients undergoing TAVI in a native valve.
Using nationwide registries, we identified all Danish citizens, who underwent TAVI from January 1, 2008, to December 31, 2020.
A total of 6,070 patients undergoing TAVI were identified; 247 (4%) patients had a history of SAVR (The valve-in-valve cohort). The median age of the study population was 81 (25th-75th percentile 77-85) and 55% were men. Patients with valve-in-valve-TAVI were younger but had a greater burden of cardiovascular comorbidities compared with patients with native-valve-TAVI. Within 30 days post procedure, 11 (0.2%) and 748 (13.8%) patients who underwent valve-in-valve-TAVI and native-valve-TAVI, respectively, had a pacemaker implantation. The cumulative 30-day risk of death among patients with valve-in-valve-TAVI was 2.4% (95% CI: 1.0%-5.0%) and 2.7% (95% CI: 2.3%-3.1%) in patients with native-valve-TAVI, respectively. Correspondingly, the cumulative 5-year risk of death was 42.5% (95% CI: 34.2%-50.6%) and 44.8% (95% CI: 43.2%-46.4%), respectively. In multivariable Cox proportional hazard analysis, valve-in-valve-TAVI was not associated with a significantly different risk of death at 30 days (Hazard ratio (HR) = 0.95, 95% CI 0.41-2.19) and 5 years (HR = 0.79, 95% CI 0.62-1.00) post-TAVI compared with native-valve-TAVI.
TAVI in a failed surgical aortic prosthesis as compared to TAVI in a native valve, was not associated with significantly different short- and long-term mortality, suggesting that valve-in-valve-TAVI is a safe procedure.
经导管主动脉瓣置换术(TAVI)是治疗外科主动脉瓣假体失效的一种可行且越来越常用的治疗选择,但临床数据有限。我们旨在研究接受外科瓣膜(瓣中瓣 TAVI)和接受原生瓣膜 TAVI 的患者的临床特征和结局。
我们使用全国性登记处,确定了 2008 年 1 月 1 日至 2020 年 12 月 31 日期间接受 TAVI 的所有丹麦公民。
共确定了 6070 例接受 TAVI 的患者;247 例(4%)患者有 SAVR 病史(瓣中瓣队列)。研究人群的中位年龄为 81 岁(25 至 75 百分位数为 77 至 85),55%为男性。与接受原生瓣膜 TAVI 的患者相比,接受瓣中瓣 TAVI 的患者年龄较小,但心血管合并症的负担更大。术后 30 天内,分别有 11 例(0.2%)和 748 例(13.8%)接受瓣中瓣 TAVI 和原生瓣膜 TAVI 的患者植入了起搏器。瓣中瓣 TAVI 患者的 30 天死亡率累积率为 2.4%(95%CI:1.0%-5.0%),而接受原生瓣膜 TAVI 的患者为 2.7%(95%CI:2.3%-3.1%)。相应地,瓣中瓣 TAVI 患者的 5 年死亡率累积率分别为 42.5%(95%CI:34.2%-50.6%)和 44.8%(95%CI:43.2%-46.4%)。多变量 Cox 比例风险分析显示,与接受原生瓣膜 TAVI 相比,瓣中瓣 TAVI 在术后 30 天(风险比(HR)=0.95,95%CI 0.41-2.19)和 5 年(HR=0.79,95%CI 0.62-1.00)的死亡风险无显著差异。
与接受原生瓣膜 TAVI 相比,在外科主动脉瓣假体失效时接受 TAVI 并不与明显不同的短期和长期死亡率相关,提示瓣中瓣 TAVI 是一种安全的手术。